Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06786390
Recruiting Not applicable

Improved Recovery of Walking in Acquired Muscle Weakness

NCT06786390 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-02-25
Last updated
2025-03-03

Condition(s) studied

Critical Illness MyopathyCritical Illness Polyneuropathy

Investigational drug(s) / intervention(s)

Rehabilitation protocol: FESRehabilitation protocol without FESRehabilitation protocol: FES

Rehabilitation protocol: FES: Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol

Rehabilitation protocol without FES: Subjects belonging to the control group will follow the rehabilitation protocol without FES

Rehabilitation protocol: FES: Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol

Study summary

The aim of Re-Walk-Easy is to evaluate the effects of rehabilitation based on electrical stimulation on the motor performance of critically ill patients. The study will also investigate the pathophysiology of the two forms-the myopathic-predominant and the polyneuropathic-predominant variants-by examining the longitudinal progression of CIP and CIM and determining which form benefits more from electrical stimulation as a rehabilitative approach.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Critical Illness Patient Inclusion Criteria: * clinical diagnosis of tetra/paraparesis of peripheral origin as disclosed by ENG/EMG examination; * be independent before the episode of critical illness Critical Illness Patient Exclusion Criteria: * history of previous comorbidity for ICU-AW; * previous known chronic polyneuropathy; * severe coagulopathy; * severe disorder of consciousness; * contraindications to Electrical Stimulation application Healthy Subjects Exclusion Criteria: * Prosthetic implants * musculoskeletal, neurological, cardiovascular and pulmonary disorders that may alter the gait

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IRCCS Fondazione Don Carlo Gnocchi Onlus Milan Italy Recruiting

More Fondazione Don Carlo Gnocchi ETS trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06786390 on ClinicalTrials.gov ↗ ← All trials in Italy